Advance Search
Volume 42 Issue 6
Jun.  2021
Turn off MathJax
Article Contents
Abstract
References
HAN Chun, YE Sisi, LI Juan, QIAO Qian, ZHANG Wensheng. Clinical outcomes of nimotuzumab combined with gemcitabine as first-line treatment for advanced pancreatic cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2021, 42(6): 596-600, 614. DOI: 10.3969/j.issn.2095-5227.2021.06.002
Citation: HAN Chun, YE Sisi, LI Juan, QIAO Qian, ZHANG Wensheng. Clinical outcomes of nimotuzumab combined with gemcitabine as first-line treatment for advanced pancreatic cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2021, 42(6): 596-600, 614. DOI: 10.3969/j.issn.2095-5227.2021.06.002
shu

Clinical outcomes of nimotuzumab combined with gemcitabine as first-line treatment for advanced pancreatic cancer

  • Department of Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China

Funds: Supported by the National Key Research and Development Program of China (2016YFC1303602)
More Information
  • Corresponding author:

    HAN Chun. Email: hanchun301@sina.com

  • Received Date: January 23, 2021
  • Available Online: October 18, 2021
    Graphical Abstract
    • Abstract
  •   Background  Nimotuzumab is a targeted drug targeting epidermal growth factor receptor (EGFR), which has achieved good outcomes in clinical trials abroad, while domestic clinical data in large scale is relatively small.
      Objective  To investigate the outcomes and safety of nimotuzumab combined with gemcitabine (GEM) as the first-line treatment for advanced pancreatic cancer.
      Methods  Through the big data platform of our hospital, clinical data about patients with advanced pancreatic cancer from January 2012 to June 2019 were searched. According to the inclusion criteria, the cases in line with this study were selected, and divided into combined therapy group (nimotuzumab + GEM monotherapy) and monotherapy group (GEM monotherapy). After matching by sex, age, and differentiation, 61 cases were included in each group, and the differences of adverse reactions, progression free survival (PFS) and overall survival (OS) between the two groups were analyzed.
      Results  The combined therapy group had significantly longer PFS (4.5 months vs 3.1 months, P＜0.001) and OS (7.4 months vs 6.4 months, P＜0.001) compared to the monotherapy group. Further, Cox regression analysis showed that GEM combined with nimotuzumab was associated better prognosis in patients with advanced pancreatic cancer (P＜0.001). There was no significant difference in the incidence of treatment-related adverse events between the two groups (P＞0.05).
      Conclusion  Compared with GEM monotherapy, nimotuzumab combined with GEM in the first-line treatment of advanced pancreatic cancer can increase the survival benefits without increasing toxic and side effects, which is an alternative first-line treatment for patients with advanced pancreatic cancer.
    • FullText(HTML)
    • References (19)
  • [1]
    Siegel RL,Miller KD,Jemal A. Cancer statistics,2019[J]. CA Cancer J Clin,2019,69(1): 7-34. doi: 10.3322/caac.21551
    [2]
    Neoptolemos JP,Kleeff J,Michl P,et al. Therapeutic developments in pancreatic cancer:current and future perspectives[J]. Nat Rev Gastroenterol Hepatol,2018,15(6): 333-348. doi: 10.1038/s41575-018-0005-x
    [3]
    中国临床肿瘤学会（CSCO）. 胰腺癌诊疗指南2020［M］. 北京: 人民卫生出版社, 2020.
    [4]
    Sohal DPS,Kennedy EB,Khorana A,et al. Metastatic pancreatic cancer:ASCO clinical practice guideline update[J]. J Clin Oncol,2018,36(24): 2545-2556. doi: 10.1200/JCO.2018.78.9636
    [5]
    Conroy T,Desseigne F,Ychou M,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med,2011,364(19): 1817-1825. doi: 10.1056/NEJMoa1011923
    [6]
    Yamaoka T,Ohba M,Ohmori T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms[J]. Int J Mol Sci,2017,18(11): 2420. doi: 10.3390/ijms18112420
    [7]
    Kaushik G,Seshacharyulu P,Rauth S,et al. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis[J]. Oncogene,2021,40(4): 848-862. doi: 10.1038/s41388-020-01564-w
    [8]
    Wang X,Wu XY,Zhang ZL,et al. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway[J]. Sci Rep,2018,8(1): 17914. doi: 10.1038/s41598-018-36214-5
    [9]
    Chen H,He RZ,Shi XH,et al. Meta-analysis on resected pancreatic cancer:a comparison between adjuvant treatments and gemcitabine alone[J]. BMC Cancer,2018,18(1): 1034. doi: 10.1186/s12885-018-4948-7
    [10]
    Wang Z. ErbB Receptors and Cancer［J］. Methods Mol Biol, 2017, 1652: 3-35.
    [11]
    Verma HK,Kampalli PK,Lakkakula S,et al. A retrospective look at anti-EGFR agents in pancreatic cancer therapy[J]. Curr Drug Metab,2019,20(12): 958-966.
    [12]
    Crombet-Ramos T,Rak J,Pérez R,et al. Antiproliferative,antiangiogenic and proapoptotic activity of h-R3:A humanized anti-EGFR antibody[J]. Int J Cancer,2002,101(6): 567-575. doi: 10.1002/ijc.10647
    [13]
    Hartimath SV,Alizadeh E,Solomon VR,et al. Preclinical evaluation of 111In-labeled PEGylated maytansine nimotuzumab drug conjugates in EGFR-positive cancer models[J]. J Nucl Med,2019,60(8): 1103-1110. doi: 10.2967/jnumed.118.220095
    [14]
    Zhou CF,Zhu LJ,Ji J,et al. EGFR high expression,but not KRAS status,predicts sensitivity of pancreatic cancer cells to nimotuzumab treatment in vivo[J]. Curr Cancer Drug Targets,2017,17(1): 89-97.
    [15]
    Schultheis B,Reuter D,Ebert MP,et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer:a multicenter,randomized phase IIb study[J]. Ann Oncol,2017,28(10): 2429-2435. doi: 10.1093/annonc/mdx343
    [16]
    杨丽丽. 尼妥珠单抗与吉西他滨联合顺铂化疗方案在晚期胰腺癌治疗中的应用[J]. 河南医学研究,2017,26(15): 2766-2767. doi: 10.3969/j.issn.1004-437X.2017.15.047
    [17]
    王尧,钟国成,李迎春,等. 尼妥珠单抗联合盐酸吉西他滨治疗高表达表皮生长因子受体中晚期胰腺癌患者的临床研究[J]. 成都医学院学报,2020,15(5): 615-618. doi: 10.3969/j.issn.1674-2257.2020.05.017
    [18]
    吴振林. 用尼妥珠单抗、吉西他滨联合顺铂对晚期胰腺癌患者进行化疗的效果分析[J]. 当代医药论丛,2019,17(6): 138-139. doi: 10.3969/j.issn.2095-7629.2019.06.100
    [19]
    Joshi A,Patil VM,Noronha V,et al. Nimotuzumab dosing and outcomes in locally advanced head and neck cancer[J]. Clin Oncol,2020,32(1): e36. doi: 10.1016/j.clon.2019.07.006
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (245) PDF downloads (8) Cited by()
    Related
    Contact Us
    • Phone：(010)66936767
    • Email： xuebao301@vip.163.com
    • Address：PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, China
    Download Center
    Links

    Copyright © Editorial Department of Journal of PLA Medical College 京ICP备17052889号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return